A randomised study of tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy for early breast cancer (SBG 2000-1)
Henrik Lindman(Uppsala University), Carl Blomqvist(University of Helsinki), Johan Ahlgren(Gävle Hospital), Eva Balslev(University of Copenhagen), Bent Ejlertsen, Anders Bonde Jensen(Aarhus University Hospital), Ásgerður Sverrisdóttir(Uppsala University Hospital), Jonas Bergh(Karolinska Institutet), Malgorzata Tuxen(University of Copenhagen), Michael Andersson(University of Copenhagen), H. Anderson(The Medical Device (United Kingdom)), Nils‐Olof Bengtsson, Kenneth Villman(Örebro University Hospital), E.H. Jacobsen(Vejle Sygehus), Stig B. Holmberg(Sahlgrenska University Hospital), Jean M. Hansen(Västerås Municipality), Lena Malmberg(Karlstad Central Hospital)
Cited by 4
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k